Mechanism of Action of Mycophenolate Mofetil

@article{Ransom1995MechanismOA,
  title={Mechanism of Action of Mycophenolate Mofetil},
  author={J. Ransom},
  journal={Therapeutic Drug Monitoring},
  year={1995},
  volume={17},
  pages={681–684}
}
  • J. Ransom
  • Published 1995
  • Chemistry, Medicine
  • Therapeutic Drug Monitoring
Summary Mycophenolate mofetil is a prodrug which is rapidly converted to mycophenolic acid (MPA), a potent and reversible uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). In the de novo purine synthesis pathway, IMPDH is the first of two enzymes responsible for the conversion of inosine monophosphate (IMP) to guanosine monophosphate (GMP), which is normally converted to GDP, GTP, and dGTP. IMPDH is not involved in the salvage pathway of purine biosynthesis. It has been… Expand
Assessment of mycophenolic acid-induced immunosuppression: a new approach.
TLDR
Measurement of the inhibition of CEM cell line proliferation by sera from MMF-treated patients may be useful for evaluating the relative efficacy of MMF treatment in individual patients, especially those receiving low doses of MMf. Expand
Influence of mycophenolic acid on inosine 5'-monophosphate dehydrogenase activity in human peripheral blood mononuclear cells.
TLDR
The chromatographic method presented in this report allows a rapid, reliable and reproducible quantification of IMPDH activity in PBMCs and therefore represents an attractive tool for the pharmacodynamic monitoring of the effects of MPA in patients under immunosuppressive therapy. Expand
Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase.
TLDR
AcMPAG is a weaker inhibitor of rhIMPDH II than MPA and is less concentrated in lymphocytes in vitro, suggesting that it would not be pharmacologically active in vivo and might not need to be monitored in MPA-treated patients. Expand
Case Study: Mycophenolate Mofetil
Mycophenolate mofetil (MMF) is an orally bioavailable prodrug of mycophenolic acid (MPA), a potent immunosuppressive agent. MPA acts by inhibiting inosine monophosphate dehydrogenase (IMPDH), whichExpand
VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent.
TLDR
It is demonstrated that VX-497 is a potent, specific, and reversible IMPDH inhibitor that selectively inhibits lymphocyte proliferation in this model of immune activation. Expand
Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity.
TLDR
Data support the proposal that MPAG is a pharmacologically inactive metabolite of MPA, with inhibitory concentrations found to be 532- to 1022-fold higher than those for MPA. Expand
Therapeutic drug monitoring of mycophenolic acid.
TLDR
The pertinent information and study data regarding the current understanding of MPA PK and major factors that can influence MPA clearance are discussed, the performance of MMF in many maintenance immunosuppression regimens, the complex pharmacokinetics (PK) of M PA, and the absence of overt organ toxicity are reviewed. Expand
PHARMACOKINETICS OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS
Mycophenolate Mofetil (MMF) is an ester prodrug of the immunosuppressant myco-phenolic acid (MPA), which selectively inhibits the inosine monophosphate dehydrogenase (IMPDH). IMPDH converts inosineExpand
Mycophenolic acid-induced apoptotic signal transduction in MOLT-4 T-cell.
TLDR
It is suggested that MPA induces the apoptotic death of MOLT-4 lymphocytes via the activations of caspase family proteases and the depletion of GTP. Expand
Activation of the Purine Salvage Pathway in Mononuclear Cells of Cardiac Recipients Treated with Mycophenolate Mofetil
TLDR
It is demonstrated for the first time an induction of salvage pathway enzyme activities in PBMC under MMF therapy, which probably accounts for the maintenance of intracellular purine nucleotide pools and prevents the GTP depletion. Expand
...
1
2
3
4
5
...